Abbvie Inc (ABBV) Dividends

For an income-focused value investor, AbbVie presents a mixed but generally favourable dividend profile. The dividend appears sustainable, with a free cash flow yield of 4.9% comfortably covering the 3.18% dividend yield. This indicates the company generates sufficient cash to support the payout, a key quality indicator. The dividend has a history of growth, as implied by the company's status as a Dividend Aristocrat, though the current data does not specify the recent growth rate. The primary caution relates to the payout ratio. With a P/E ratio of 86.6 and an EPS of $2.36, the earnings-based payout ratio is very high, but this is misleading due to large non-cash amortization charges from past acquisitions. The more relevant metric is the free cash flow coverage, which is strong. Compared to the sector, AbbVie's 3.18% yield is below the average for large-cap pharmaceuticals, which often trade in the 4-5% range, making it less attractive for pure yield seekers. From a quality perspective (Section 2 of the framework), the strong FCF generation is positive, but the high P/E and modest 10% YoY revenue growth warrant scrutiny to ensure the dividend growth can continue without compromising financial strength. The 'GoodMoat Target' price of $131.68, significantly below the current price, suggests the stock may be overvalued, which could compress future yield-on-cost for new investors. Analysis based on data as of 2024-05-15.